| scholarly article | Q13442814 |
| P2093 | author name string | J Wu | |
| Y Luo | |||
| Y Ji | |||
| M Luo | |||
| R Li | |||
| W P Fay | |||
| P2860 | cites work | Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation | Q42738253 |
| Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix | Q43858114 | ||
| Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation | Q43939747 | ||
| Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin | Q44850338 | ||
| Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. | Q45944655 | ||
| Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides | Q47881843 | ||
| Significance of vitronectin and PAI-1 activity levels in carotid artery disease: comparison of symptomatic and asymptomatic patients. | Q50864888 | ||
| Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein. | Q53460186 | ||
| Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis | Q57222793 | ||
| Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall | Q69102361 | ||
| Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin | Q70523860 | ||
| Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: a potential progenitor of restenosis | Q72811871 | ||
| Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1 | Q73203966 | ||
| Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque | Q74251022 | ||
| Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein | Q74299355 | ||
| Recognition of alpha 2-macroglobulin by the low density lipoprotein receptor-related protein requires the cooperation of two ligand binding cluster regions | Q74379625 | ||
| Binding of receptor-recognized forms of alpha2-macroglobulin to the alpha2-macroglobulin signaling receptor activates phosphatidylinositol 3-kinase | Q74567337 | ||
| C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance | Q80706514 | ||
| The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin | Q24310652 | ||
| Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration | Q24546040 | ||
| Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity | Q24633333 | ||
| Regulation of proteolytic enzymes and inhibitors in two smooth muscle cell phenotypes | Q28570169 | ||
| Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor | Q28610930 | ||
| Interaction of vitronectin with collagen | Q28645683 | ||
| Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects | Q30700072 | ||
| Vitronectin is not essential for normal mammalian development and fertility. | Q33679049 | ||
| Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization | Q33909797 | ||
| Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization | Q33979344 | ||
| Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin | Q34333539 | ||
| Vitronectin in vascular context: facets of a multitalented matricellular protein | Q34631318 | ||
| Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue | Q34660527 | ||
| Vitronectin gene expression in vivo. Evidence for extrahepatic synthesis and acute phase regulation | Q34719534 | ||
| Localization of vitronectin in the normal and atherosclerotic human vessel wall | Q34740237 | ||
| Old dogs and new tricks: proteases, inhibitors, and cell migration | Q35167706 | ||
| The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice | Q35182731 | ||
| Mouse model of venous bypass graft arteriosclerosis | Q35753478 | ||
| The human alpha 2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin | Q36223019 | ||
| Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? | Q36237406 | ||
| Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins | Q36324236 | ||
| Vitronectin in atherosclerotic disease | Q36388057 | ||
| Molecular evolution of plasminogen activator inhibitor-1 functional stability | Q36688372 | ||
| PAI-1 antagonists: predictable indications and unconventional applications | Q36952097 | ||
| Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries | Q37131350 | ||
| Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene | Q37351382 | ||
| Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). | Q38092174 | ||
| The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. | Q40582221 | ||
| IL-6 stimulates vitronectin gene expression in vivo | Q41666791 | ||
| Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts | Q42128982 | ||
| Inhibition of HCV by the serpin antithrombin III | Q42406960 | ||
| Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices | Q42425209 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 2451-2460 | |
| P577 | publication date | 2017-10-13 | |
| P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
| P1476 | title | Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin | |
| P478 | volume | 15 |
| Q90574765 | ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma |
| Q55491477 | Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. |
| Q93093507 | Evaluation of Serum Levels of Inflammation, Fibrinolysis and Oxidative Stress Markers in Coronary Artery Disease Prediction: A Cross-Sectional Study |
Search more.